DMOG

Catalog No.S7483 Synonyms: Dimethyloxalylglycine

For research use only.

DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.

DMOG Chemical Structure

CAS No. 89464-63-1

Selleck's DMOG has been cited by 28 publications

Purity & Quality Control

Choose Selective Hydroxylase Inhibitors

Other Hydroxylase Products

Biological Activity

Description DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.
Targets
HIF prolyl hydroxylase [1]
In vitro

DMOG shows only weakly active in the microsomal system, but efficiently suppresses hydroxyproline synthesis in intact cells. [1] DMOG reduces FGF-2-induced proliferation and cyclin A expression by inhibiting prolyl hydroxylase activity in HPASMC. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human SR cell NFjoWVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jOdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW3PVQ3KM7:TR?= NVnzTZhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human LB996-RCC cell NUnxcZBmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjh5NzFOwG0> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human LOUCY cell M4[5VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1:5RmlvcGmkaYTpc44hd2ZiaIXtZY4hVE:XQ2mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4{PDl|IN88US=> MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human KS-1 cell NWD3d5ZzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml;xTY5pcWKrdHnvckBw\iCqdX3hckBMWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuNlU2PyEQvF2= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human U-698-M cell NXzBV3V3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmLjTY5pcWKrdHnvckBw\iCqdX3hckBWNTZ7OD3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvOzNyNjFOwG0> MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human A3-KAW cell NGOybXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYT1NHJUUW6qaXLpeIlwdiCxZjDoeY1idiCDMz3LRXch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS56MUe0JO69VQ>? NHrpTYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human BL-70 cell Mn;PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXP6UI05UW6qaXLpeIlwdiCxZjDoeY1idiCETD23NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2Njl2MkOg{txO NX\lZ4ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human DMS-273 cell MmrUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU46PjVizszN MnfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human CAL-39 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlMzPzdizszN MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human KYSE-410 cell MnryS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG[3cIxKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjBwOEG5O{DPxE1? M3jnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human YT cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGL2N25KdmirYnn0bY9vKG:oIHj1cYFvKFmWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkOuN|k5PCEQvF2= NFTTT3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human LC-2-ad cell NHvONGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjKO3FKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPC53NUezJO69VQ>? NXzSe3lYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human COR-L105 cell NEjicI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVP1eIY6UW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ4LkS0N|Yh|ryP NYXJSpV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human CAL-12T cell MnfyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvufIZUUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNVJVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjZwNUWwNkDPxE1? NXnIdYdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human KU812 cell NIjSTlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvn[5VTUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjR3N{mg{txO M1TNelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human OPM-2 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnvYTY5pcWKrdHnvckBw\iCqdX3hckBQWE1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlgzOjdizszN NVLUPIw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human SW982 cell NIfnfZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFX3WY9KdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|MvPzByNzFOwG0> Mkf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human HH cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGhJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwMEKzOUDPxE1? MmfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human RS4-11 cell NE\UcnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XFS2lvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvOThyNjFOwG0> M1G3XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human BEN cell MmjhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVPYXotHUW6qaXLpeIlwdiCxZjDoeY1idiCERV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOk45OTh5IN88US=> NH\Y[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human CCRF-CEM cell NVG4PWFQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlTETY5pcWKrdHnvckBw\iCqdX3hckBES1KILVPFUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM4Njd5Mkmg{txO MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human EW-13 cell MlHCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{muNFQ5OSEQvF2= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human NCI-H2228 cell MkW3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDqTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyNlgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oi56MUig{txO NIn4cFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human KE-37 cell M4mxWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnfiTY5pcWKrdHnvckBw\iCqdX3hckBMTS1|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSzMlI6OTVizszN NFXpdnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human A4-Fuk cell Mn7PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVrzWXpbUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01PS5yM{[0JO69VQ>? NX7zbpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human MZ1-PC cell M1rOUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37XXWlvcGmkaYTpc44hd2ZiaIXtZY4hVVpzLWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvQTh6ODFOwG0> M2fjcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human MLMA cell NIG5T3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\NTmlvcGmkaYTpc44hd2ZiaIXtZY4hVUyPQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS2MlMzQTJizszN MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human EB-3 cell Mm\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFm5VZRKdmirYnn0bY9vKG:oIHj1cYFvKEWELUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20PU42Pzl{IN88US=> NXLqUJdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human 293T cells  MWnGeY5kfGmxbjDhd5NigQ>? M17ubVIvPSCvTR?= M2HIdmlvcGmkaYTpc44hd2ZiSl3KSFIudWWmaXH0[YQhUDONM{[g[IVu\XSqeXzheIlwdiCrbjDoeY1idiB{OUPUJINmdGy|IHH0JFIvPSCvTR?= NF\6cpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO1PVE3Pyd-MUmzOVkyPjd:L3G+
Assay
Methods Test Index PMID
Western blot HIF-1α ; p-CHK1 / CHK1 / p-p53 / p53 / p-CHK2 / CHK2 / p-ATM / ATM ; WNT11 / HIF-2α 29555474 22797300 26861754
Immunofluorescence HIF1α 28955984
In vivo

DMOG inhibits endogenous HIF inactivation, and induces angiogenesis in ischaemic skeletal muscles of mice. [2] Up-regulation of hypoxia-inducible factor-1α by DMOG enhances the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. [4]

Protocol (from reference)

Cell Research:

[3]

  • Cell lines: VSMC cells
  • Concentrations: ~100 μM
  • Incubation Time: 72-96 hours
  • Method:

    To analyze DNA synthesis as an index of cellular proliferation, VSMC are plated in 48-well plates (5,000 per square centimeter) in growth medium, incubated overnight, and serum-deprived (1% FCS) for 24 h. Replicate wells are then stored at −70°C for baseline (day 0) cell counts, and fresh medium with or without growth factors is added to the remaining wells, which are incubated 72-96 h in 20 or 5% O2. Days 0 and 3 or 4 cell counts are determined by lysing cells in a buffer containing a fluorescent dye, which has minimal fluorescence by itself but fluoresces when bound to DNA or RNA. Absolute cell numbers are calculated by comparing the fluorescence of specimens with that of a standard curve similarly prepared using a known number of cells.

Animal Research:

[2]

  • Animal Models: Mice (C57Bl6)
  • Dosages: 8 mg in 0.5 ml saline
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 175.14
Formula

C6H9NO5

Density 1.246 g/mL
CAS No. 89464-63-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)CNC(=O)C(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy DMOG | DMOG supplier | purchase DMOG | DMOG cost | DMOG manufacturer | order DMOG | DMOG distributor